[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"primary-graft-failure\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:primary-graft-failure":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,42],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100327345","phase-1-reveal-biomarkers-of-engraftment-after-alternative-donor-hsct-100327345",false,"NCT03541889","REVEAL Biomarkers of Engraftment After Alternative Donor HSCT","Multi-institutional Prospective Pilot Research of Imaging and Blood Biomarker EValuation of Engraftment After ALlogeneic Hematopoietic Stem Cell Transplantation","REVEAL","Inclusion Criteria:\n\nGeneral\n\n* Ability to undergo 18F FLT imaging without sedation\n* Patients \\> 4 years of age and less than 80 years of age at highest risk for graft failure: cord blood HSCT, haplo HSCT, or lack of engraftment by day 28.\n* Diagnosed with a condition for which hematopoietic stem cell transplant (HSCT) is standard of care and HSCT is planned (Arm A) or occurred (Arm B)\n* In morphologic remission prior to HSCT\n* Patient or guardian able to give informed consent\n* Investigational therapies within past 28 days or planned on protocol are pre-approved by the PI or Site PI\n* Karnofsky or Lansky performance status \\> 60%\n\nArm A\n\n* A1 Cord blood recipients: Absence of donor specific antibodies to cord HLA\n* Haplo-identical recipients: ≥ 5\u002F10 and \\\u003C 7\u002F8 allele mismatch donor\n* A2- myeloablative Haplo-identical transplant is planned\n* A3- reduced intensity Haplo-identical transplant is planned (non-myeloablative is excluded)\n* A1- myeloablative or reduced intensity transplant is planned (non-myeloablative is excluded)\n* Diagnosed with a condition for which hematopoietic stem cell transplant (HSCT) is standard of care and HSCT is planned\n* Total bilirubin \\\u003C 2.5 mg\u002FdL (unless documented Gilbert's syndrome) and transaminases (ALT and AST) \\\u003C 5 x the upper limit of normal\n* Creatinine clearance or GFR \\> 60 ml\u002Fmin\u002F1.73 m2. (performed pre-HSCT)\n* FEV1 \\> 80% pre or post-bronchiolator whichever is higher and DLCO Adj \\> 70% (performed pre-HSCT if age appropriate) and Sa02 \\> 94% on room air\n* Ejection fraction \\> 50% (performed pre-HSCT)\n\nArm B\n\n• Non-engraftment recipients of HCT with any donor source (related or unrelated): primary graft failure as defined by ANC not \\> 500 for 3 consecutive days and at least 20 days after HSCT.\n\nInclusion Criteria - Donors\n\n* 1-2 cords and \\>.4\u002F6 match to recipient for each (as per current National Marrow Donor guidelines), with a dose \\>2 x 10e6 CD34 cells\u002Fkg for each cord OR \\> 5\u002F10 and \\\u003C7\u002F8 allele mismatch related donor\n* Institutional guidelines met for donor suitability\n\nExclusion Criteria:\n\n* History of psychiatric disorder which may compromise compliance with transplant protocol, or which does not allow for appropriate informed consent\n* Clinically significant systemic illness with manifestations of significant organ dysfunction which, in the judgment of the PI, or Co-I, would render the patient unlikely to tolerate the protocol therapy or complete the study\n* Presence of active malignancy from an organ system other than hematopoietic\n* Pregnant or lactating females\n* Patients who are unable or unwilling to use effective form (s) of contraception during the course of the study\n* Prior history of fluorothymidine allergy or intolerance\n* Decline enrolment on CIBMTR research protocol","ALL","4 Years","80 Years",{"count":21,"type":22},56,"ESTIMATED","INTERVENTIONAL",[25],"PHASE1","The purpose of this study is to find new tests that could help determine if the newly infused bone marrow cells are growing well after bone marrow transplantation or if new bone marrow cells are needed. The Investigator will use FLT imaging, an investigational imaging test, and collect blood samples to investigate whether the cells are growing well.",[28],"Primary Graft Failure","RECRUITING","2026-03-03",{"date":32,"type":33},"2026-03-05","ACTUAL",{"date":35,"type":33},"2021-02-05",{"date":37,"type":22},"2027-11",{"name":39,"class":40},"University of Oklahoma","OTHER",4,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":48,"targetDuration":4,"studyType":50,"phases":4,"briefSummary":51,"conditions":52,"keywords":54,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":59,"completionDateStruct":61,"leadSponsor":63,"locationsCount":65},"100221566","treatment-of-graft-failure-after-hematopoietic-stem-cell-transplantation-100221566","NCT02161783","Treatment of Graft Failure After Hematopoietic Stem Cell Transplantation","Inclusion Criteria:\n\n* Patients with primary or secondary graft failure, as defined below, may receive a second transplant:\n\n  * Primary graft failure is defined as not achieving an ANC ≥0.5x10\\^9\u002FL for three consecutive days by day 35 - 42 following the first transplant.\n  * Secondary graft failure is defined as achieving an ANC ≥0.5x10\\^9\u002FL for three consecutive days by day 35 - 42, but subsequently drops below 0.5x10\\^9\u002FL without recovery.\n  * Loss of chimerism is defined as achieving an ANC ≥0.5x10\\^9\u002FL for three consecutive, but with less than 10% CD15+ donor cells in the marrow or peripheral blood.\n* Recipients should have acceptable organ function defined as:\n\n  * Renal: creatinine \\\u003C 2.0 (adults) and creatinine clearance \\> 30. For creatinine clearance \\\u003C 70, consultation with a BMT pharmacist is necessary for chemotherapy dose adjustments.\n  * Hepatic: bilirubin, AST\u002FALT, ALP \\\u003C 10 x upper limit of normal\n  * Cardiac: left ventricular ejection fraction \\> 40%\n\nExclusion Criteria:\n\n* Uncontrolled infection at the time of transplant.\n* Patients with Fanconi Anemia or other DNA breakage syndromes.",{"count":49,"type":22},50,"OBSERVATIONAL","This is a guideline for the treatment of graft failure after hematopoietic stem cell transplant (HSCT). This regimen, consisting of cyclophosphamide and fludarabine with low dose total body irradiation (TBI) is designed to promote donor engraftment by day 42 after initial graft failure.\n\nThe graft will consist of bone marrow or G-CSF mobilized peripheral blood from a haploidentical related donor. The source of stem cells will be determined by the transplant team based on factors such as patient's age, medical history, donor availability and will be according to the current University of Minnesota Blood and Marrow Transplantation Program selection guidelines.",[28,53],"Secondary Graft Failure",[55],"Hematopoietic stem cell transplant","2026-01-02",{"date":58,"type":33},"2026-01-06",{"date":60,"type":33},"2014-10-06",{"date":62,"type":22},"2032-01-30",{"name":64,"class":40},"Masonic Cancer Center, University of Minnesota",1]